Aurinia targets $305M-$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
Source: SeekingAlpha
2026-02-26 15:28:40 ET
More on Aurinia Pharma
- Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
- Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms
- Seeking Alpha’s Quant Rating on Aurinia Pharma
- Historical earnings data for Aurinia Pharma
- Financial information for Aurinia Pharma
Read the full article on Seeking Alpha
For further details see:
Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
Aurinia Pharmaceuticals Inc
NASDAQ: AUPH
AUPH Trading
4.17% G/L:
$14.82 Last:
256,009 Volume:
$14.41 Open:
AUPH Latest News
AUPH Stock Data
$1,932,123,392
126,527,384
2.24%
102
N/A
Biotechnology & Life Sciences
Healthcare
CA
Edmonton
